A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Published:2020-01 Issue:1 Volume:156 Page:23-31
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Vergote Ignace,Heitz Florian,Buderath Paul,Powell Matthew,Sehouli Jalid,Lee Christine M.,Hamilton Anne,Fiorica James,Moore Kathleen N.,Teneriello Michael,Golden Lisa,Zhang Wei,Pitou Celine,Bell Robert,Campbell Robert,Farrington Daphne L.,Bell-McGuinn Katherine,Wenham Robert M.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference27 articles.

1. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data;Raja;Ann. Oncol.,2013

2. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J. Clin. Oncol.,2006

3. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse;Pujade-Lauraine;J. Clin. Oncol.,2010

4. Management and treatment of recurrent epithelial ovarian cancer;Armbruster;Hematol. Oncol. Clin. N. Am.,2018

5. Optimizing treatment in recurrent epithelial ovarian cancer;Corrado;Expert Rev. Anticancer Ther.,2017

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapy in high grade serous ovarian Cancer: A literature review;Gynecologic Oncology Reports;2024-08

2. EBP1 promotes the malignant biological behaviors of kidney renal clear cell carcinoma through activation of p38/HIF-1α signaling pathway;Cancer Cell International;2024-07-24

3. The interplay of p38 MAPK signaling and mitochondrial metabolism, a dynamic target in cancer and pathological contexts;Biochemical Pharmacology;2024-07

4. Synthesis and reactions of novel imidazo[4,5-b]pyridine building blocks;Chemistry of Heterocyclic Compounds;2024-04

5. Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer;MedComm;2024-04